Antioxidant drug in neuroprotective therapy for glaucoma

Authors:
E.A. EGOROV¹, A.A. GVETADZE¹, N.G. DAVYDOVA²

¹Pirogov Russian National Research Medical University;
²Helmholtz Moscow Research Institute of Eye Diseases of the Russian Ministry of Health

Place of publication:
VESTNIK OPHTHALMOLOGII, No. 2, 2013

Abstract:
The aim of this study was to evaluate the efficacy and safety of Mexidol as part of a combination treatment for primary open-angle glaucoma (POAG). Ninety-four patients (185) aged 18 to 75 years with stages I–III POAG participated in the study. They were divided into three groups: 50 patients received a combination of 100 mg Mexidol and 150 mg Picamilon, 22 patients took 300 mg Mexidol and 150 mg Picamilon, and 22 patients received only 150 mg Picamilon. Patients took the medications once daily for 14 or 21 days. The examination included a standard ophthalmological examination, as well as perimetry, electroretinography, and a study of retinal arterial blood flow and the optic nerve head. After receiving combination therapy, improvements in visual acuity, perimetry parameters, electrophysiological parameters, and increased retinal arterial blood flow were observed. Thus, combination therapy can improve treatment outcomes for patients with POAG.